Exhibit 99.2

 INVESTORpresentation  March 2022  Ofer Haviv, President & CEO 

 Forward Looking Statement  This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.  2 

 Agenda  IntroductionFields of activityMain subsidiariesSummary  3  Annex I - TechnologyAnnex II - Financial Fundamentals 

 Our Vision  4  DECODING BIOLOGY  Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies. 

 Life-science product development Low probability of success with high cost and long time-to-market   Pharmaceutical Industry  Ag-chemicalsIndustry  In the 1970’s  2000’s – 2017  $180 million  Cost of developing a single pharmaceutical drug  $2.7 billion  Time to develop a new crop protection product    1995  2000  2005-8  2010-15  Number of years between the first synthesis and first sale of product  8.3  9.1  9.8  11.3  Sources: CDER (Center for Drug Evaluation and Research), Food and Drug Administration, Tufts Center for the Study of Drug Development: https://www.sciencedirect.com/science/article/abs/pii/S0167629616000291?via%3Dihubhttps://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa82d459  Source: Phillips McDougall, 2016 

 Life-science product development The ultimate case of a needle in the haystack  Regulation  Development   Optimization  Discovery            Agriculture      xxx  xxx  Pharma  6    ApprovedProduct  Product Candidates  The challenge: Finding the winning candidates out of a vast number of possible prospects, that address a complex myriad of criteria to reach successful products 

 Utilizing an advanced computational biology platform, to identify the most promising candidates addressing multiple development challenges, towards successful life-science products:Increase probability of success Reducing time and cost   7  HUMAN HEALTH  Agriculture  Other Industries  The opportunity 

 When biology meetsdisruptive technologies   platform  8  BIG DATA  BIOLOGY  AI  Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), to successfully discover & guide the development of novel life-science based products.  – Computational Predictive Biology 

 Tailor-made Engines for product discovery & development   The CPB platform enhances product discovery and development through dedicated Engines for products based on three core components:MicrobesSmall molecules Genetic elements   9      MICROBES  GENETIC ELEMENTS  SMALL MOLECULES 

   10  AGRICULTURE & FOOD  PHARMA & WELLNESS  OTHER INDUSTRIES  PlasticDegradation  Chemicals  Source forEnzymes  Oil SpillClearing  WastewaterTreatments  Microbialsfor Crops  Food  Human &Animal Probiotics  Therapeuticmicrobials  Probiotics  DietarySupplements  Developing an eco-system around our tech engines  Case Study – Potential uses for MicroBoost AI 

     11  User Interface 

 Product-oriented subsidiaries powered by Evogene’s technologyEstablish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development.   12  Business Model  Microbiome based therapeutics  Medical cannabis  Ag-solutions for castor  Ag-chemicals  Ag-biologicals  1  Licensed to use Evogene’s technological engines:  Subsidiaries: 

 13  Business Model  Collaborations powered by Evogene’s technology for the development of innovative productsJoint development with leading companies for defined products utilizing Evogene’s unique solution. Typically, partner leads later-stage development and product commercialization.  2  Powered by Evogene’s technological engines:  Collaborations for product development: 

 Agenda  IntroductionFields of activityMain subsidiariesSummary  14  Annex I - TechnologyAnnex II - Financial Fundamentals 

 15  Current life-science based products powered by Evogene’s tech-engines  OTHER INDUSTRIES  AGRICULTURE  HUMAN HEALTH        Ag-Biologicals  MicrobiomebasedTherapeutics  MICROBES      Ag-Chemicals  Drugs based on small molecules  SMALL MOLECULES    Ag-solutionsfor castoroil production  Seed Traits  MedicalCannabis  GENETIC ELEMENTS       

 16  OTHER INDUSTRIES  AGRICULTURE  HUMAN HEALTH            MICROBES          SMALL MOLECULES          GENETIC ELEMENTS        Seed Traits [division]  *  * Non-exclusive license  Development & commercialization through subsidiaries and collaborations 

   Evogene Group  17      *Evogene holdings  Other Industries  100%*  Castor Oil ProductionCastor seeds &growth protocols  HumanHealth  Microbiome basedTherapeuticsImmuno-oncologyGI- gastrointestinal- related disordersMDRO – multi-drug resistant organisms  Medical CannabisHigh yield & consumer traitsTherapeutic traits – currently inflammation & pain  93%*  100%*  Seed TraitsYield improvement and drought tolerancePlant diseaseInsect control  Agriculture  Ag ChemicalsHerbicidesInsecticidesFungicides  Ag BiologicalsBio-StimulantsBio-Pesticides  98%*  70%* (28% Corteva)  Internal division of Evogene  

                 Microbiome Based Therapeutics    Medical Cannabis    Ag-Biologicals    Ag-Chemicals    Company Name  Market Cap/Funds Raised  Company Name  Market Cap/Funds Raised  Company Name  Market Cap/Funds Raised  Company Name  Market Cap/Funds Raised    $166m*    $1.6B*    Raised $116m# (Sep 2021)    Raised $24m#(Jan 2017)    $320m*    $4.3B*    €192m*    Raised $45m# (June 2020)    $651m*    $141m*    $126m*    Raised $55m# (Feb 2020)    $68m*    $290m*    Raised $430m$2.0B## rep.(July 2021)    Raised $10m#(Oct 2021)  Main Subsidiaries: Industry Landscape  18      * Public company – market cap as of March 9, 2022 (yahoo.finance.com) # Private company – amount raised in most recent financing round (crunchbase.com)## Private company - https://www.forbes.com/sites/amyfeldman/2021/07/19/pivot-bio-nears-2-billion-valuation-as-it-raises-whopping-430-million-to-replace-synthetic-fertilizers-on-corn-and-wheat-sustainability/?sh=96ed3572273a  The table presents valuation or amount raised in last financing round for a selected number of companies active in the same industries as our subsidiaries, is not a comprehensive list, and is presented for informational purposes only. There may be significant differences between companies active in each industry, and therefore the table does not indicate potential value for our subsidiaries, which may have no correlation to the information presented in the table and may differ significantly. Such differences may include, among others, company maturity stage, volume of sales, if any, product types, target market segments, pipeline maturity, technology, and financial position.      

 Agenda  IntroductionFields of activityMain subsidiariesSummary  19  Annex I - TechnologyAnnex II - Financial Fundamentals 

     20  Immuno-oncology program:Combination therapy for cancer with checkpoint inhibitorsPre-clinical stageAddressable market size expected by 2026* – $243BGI related disorders:Inflammatory Bowel Disorder (IBD) – pre-clinical stageIrritable Bowel Syndrome (IBS) – discovery stageAddressable market size expected by 2026: Inflammatory Bowel Disorder $22.4B, Irritable Bowel Syndrome** $3.3BMDRO:Multi Drug Resistant Organisms (antimicrobial resistance)Clostridium Difficile Infection (CDI) – discovery stageMethicillin-resistant Staphylococcus aureus (MRSA) – discovery stageAddressable market size expected by 2026: CDI*** $1.7B, MRSA**** $3.9B  Mission:Discovery and development of novel therapies for microbiome-related human disorders using computational biology  2022IBD - initiate scale-up for GMP production of drug candidate for IBDImmuno-oncology - readout from proof of concept, first in human study2023IBD - Clinical batch production of drug candidate for IBD as preparation for Phase 1 in USA Immuno-oncology - Pre-IND Meeting with FDA  Product Pipeline:  | Human Microbiome  *https://www.globenewswire.com/news-release/2019/07/17/1884118/0/en/Cancer-Immunotherapy-Market-To-Reach-USD-242-86-Billion-By-2026-Reports-And-Data.html**https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market?utm_source=blog.goo.ne.jp&utm_medium=referral&utm_campaign=Vrushali_7Aug_hc_InflammatoryBowelDiseaseTreatmentMarket_pr&utm_content=Content; https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market#:~:text=Report%20Overview,4.4%25%20from%202018%20to%202026.., https://www.bloomberg.com/press-releases/2019-07-23/ibs-treatment-market-size-worth-3-3-billion-by-2026-cagr-10-1-grand-view-research-inc***https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market?utm_source=blog.goo.ne.jp&utm_medium=referral&utm_campaign=Vrushali_7Aug_hc_InflammatoryBowelDiseaseTreatmentMarket_pr&utm_content=Content; https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market#:~:text=Report%20Overview,4.4%25%20from%202018%20to%202026..www.globaldata.com/global-clostridium-difficile-infections-market-approach-1-7-billion-2026/****www.prnewswire.com/news-releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-reach-over-us-39-billion-by-2025-upsurge-in-the-consumption-of-antibiotics-across-the-globe-to-fuel-market-growth-observes-transparency-market-research-676949593.html        Expected main near-term value drivers:    Powered by 

     21  Example Results:   Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone  Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo  | Human Microbiome 

   22  MetaYield+ Products:Stable enhancement of total plant compounds:Increased compounds per plantIncreased compounds per areaTotal Cannabis market size expected by 2024 – $42.7B* Precise+ Products:Stable enhancement of specific active compounds for pain and inflammation: Medical indication focusCompound profile focusTotal Medical Cannabis market size expected by 2024 – $25.6B*  2022MetaYield+ - commercial launch and sales of second- generation products in IsraelPrecise + - Collect clinical data to support commercial launch in 2023 of variety reducing pain or inflammation2023MetaYield+ - commercial launch and initial sales of first product in EuropePrecise+ - Commercial launch of variety reducing pain or inflammation  Product Pipeline:  | Medical Cannabis  *Source: Arcview Market research/BDS Analytics 2020  Expected main near-term value drivers:        Powered by    Mission:Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect 

     23  First Products:  Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes  MetaYield products– increased compounds per area, addressing the T20/C4 (17%-24% THC & 1%-7% CBD) and T15/C3 (11%-19% THC & 0.5%-5.5% CBD) market segments.  | Medical Cannabis 

   24  Herbicides:Novel MoA (Mode-of-Action) selective/non-selective herbicidesRelevant target crops – Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBDAddressable market size expected by 2022*: $34BLead stage Insecticides:Novel SoA (Site-of-Action)Addressable market size expected by 2022*: $19BHit-to-Lead stage  2022New MoA Herbicide – enter an additional collaboration agreement New MoA Herbicide – expand data package for APTH1, AgPlenus’ leading new MoA protein for the development of novel herbicides 2023New MoA Herbicide – phase advancement in one of the ongoing collaborationsNew MoA Fungicide program – initial greenhouse readouts  Product Pipeline:  | Ag-Chemicals  *https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-market-2022---research-and-markets-300458389.html; https://www.marketsandmarkets.com/Market-Reports/insecticide-market-142427569.html  Expected main near-term value drivers:        Powered by    Mission:Design next-generation, effective and sustainable crop protection products by leveraging predictive biology & chemistry 

   25  Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1  | Ag-Chemicals  Greenhouse testing of APH1 – modified tobacco plants with resistance trait vs unmodified control  (weed)    Example Results:   New MoA Herbicide - APH1 

   26  | Ag-Biologicals  Bio-stimulants (yield enhancement):Bio-stimulants 1– focus on wheat and additional cereals. Seed treatment/soil application. Commercial stage, first sales planned in 2022. Addressable market size*: for spring wheat ±25M acres.Bio-stimulants 2 – focus on corn and additional crops. Seed treatment. Pre-development stage. Addressable market size*: for corn – 120M acres.Bio-pesticides (crop protection):Fruit rots – focus on fruit and vegetables. Foliar application. Target market*: >$1B of chemicals usage. Development stage 2.Downey Mildew – Focus on fruit and vegetables. Foliar application. Development stage 1. Target market*: >$350M of chemicals usage. Seedling disease – for corn and soy. Seed treatment. pre-development stage. Target market*: >$500M.Bio-insecticides – for corn and soy. Seed treatment/foliar. Pre-development stage. Target market *: >$1.5B existing traits & chemicals market.  2022Bio-stimulants – build infrastructure for scale-up in ‘result™’ sales for spring wheat in 2023Fruit rot bio-fungicides – file for regulatory approval for leading product candidate LAV311 for fruit rot 2023Bio-stimulants – ‘result™’ product sales expansion in US and Canada for spring wheatBio-fungicides - file for regulatory approval for leading product candidate LAV321 or LAV322 for downy mildew  Product Pipeline:  *Dean ,R ,.et al. (2012). The top 10 fungal pathogens in molecular plant pathology. Molecular Plant Pathology 13:414-430 (https://academic.oup.com/fqs/article/2/3/111/5057759)  Expected main near-term value drivers:        Powered by    Mission:Improve food quality, sustainability and agriculture productivity through microbiome based ag-biologicals technology and products 

   27  | Ag-Biologicals  Example of treatment against Botrytis Cinerea in vines – untreated control vs treated vines  Lavie Bio’s wheat field in the USA during harvest – initial sales in 2022      Example Results:   - result™ inoculant (bio-stimulant)- LAV 311 & LAV 312 leading bio-fungicide candidates for fruit rot 

 SubsidiariesExpected main near-term value drivers    2022    2023      IBD – initiate scale-up for GMP production of drug candidate for IBD  Immuno-oncology – readout from proof-of-concept, first in human study  IBD – clinical batch production of drug candidate for IBD as preparation for Phase 1 clinical trials in USA  Immuno-oncology – pre-IND meeting with FDA    MetaYield – commercial launch of second- generation products in Israel  Precise – collect user data for clinical indications to support commercial launch in 2023   MetaYield – commercial launch of first product in Europe  Precise – commercial launch of first product in Israel    New MoA herbicides – enter an additional collaboration agreement   New MoA herbicide – expand data package for APTH1, AgPlenus’ leading new MoA protein for the development of novel herbicides   New MoA herbicides – reach milestone in one of the ongoing collaborations  New MoA fungicide – initial greenhouse readouts    Bio-stimulants – build infrastructure for scale-up in ‘result™’ sales for spring wheat in 2023  Bio-fungicides – file for regulatory approval for leading product candidate LAV311 for fruit rot   Bio-stimulants – ‘result™’ product sales expansion in US and Canada for spring wheat  Bio-fungicides - file for regulatory approval for leading product candidate LAV321 or LAV322 for downy mildew  28   

 Agenda  IntroductionFields of activityMain subsidiariesSummary  29  Annex I - TechnologyAnnex II - Financial Fundamentals 

 140  30  30  56  Employees  %  PhDs  %  Women  Computational systems biology  Molecular biology  Genetics  Computational chemistry  Microbiology  Biochemistry  Bioinformatics  Incl. chairpersonof the board 

 31  Summary  Our vision - Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.  CPB platform - a unique technology platform stemming from the incorporation of deep scientific understandings of biology together with big-data and artificial intelligence technologies  The CPB’s three unique engines target to improve the development of products based on the following core components:MicroBoost AI – for products based on microbesChemPass AI – for products based on small moleculesGeneRator AI – for products based on genetic elements  Four main market-oriented subsidiaries, each with a clear milestone roadmap: Biomica – human-microbiome based therapeuticsCanonic – medical cannabisAgPlenus – ag-chemicalsLavie Bio – ag-biologicals  Dual based business model - utilizing Evogene’s solutions for:Product development & commercialization through subsidiariesProduct development & commercialization through collaborations  Significant catalysts expected in the next 12 months across the subsidiaries and in Evogene’s technological offering 

 THANK You! 

 Annex I:Technology  33 

               34    Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch  Candidate Selection    ProductDefinition              Discovery  Development  The challenge in creatinglife-science based products 

               35    Candidate Selection    ProductDefinition          Common practiceDiscovery – selection of product candidates mainly addressing efficacy   The challenge in creatinglife-science based products  Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch 

               36    Candidate Selection  ProductDefinition            Low probability of successLong time to marketHigh development costs      Development – inefficient optimization & difficulty in addressing a single challenge without impairing others  The challenge in creatinglife-science based products  Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch  Common practiceDiscovery – selection of product candidates mainly addressing efficacy  

 Evogene’s AI-based solution:Discovery  37    Candidate Selection  ProductDefinition          A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI.                  Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch 

 Evogene’s AI-based solution:Development  38    Candidate Selection  ProductDefinition          A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes.                Efficacy  Safety  Selectivity  Shelf-life  Other  ProductLaunch 

 39  Evogene’s AI engines provide tailor-made solutions   Development Computational driven solution for guiding and assessing the optimization process of the selected core component, without impairing other key product attributes.   DiscoveryComputational prediction of candidates, to serve as the product’s core-component, addressing multiple key product attributes.       

 Annex II:Financial Fundamentals  40 

 Key Financials:Balance Sheet  Key Points:Consolidated cash position: ~$54 million as of 31.12.2021, of which ~$8 million is appropriated to Lavie BioNo bank debtListed on TASE (2007) and NASDAQ (2016)  1  Thousands of US $  31.12.2021  31.12.2020  Current Assets  56,890  51,823  Long-Term Assets  19,414  20,092  Total Assets  76,304  71,915  Current Liabilities  6,882  9,676  Long-Term Liabilities  6,002  5,357  Equity attributable to equity holders of the Company  54,031   46,045  Non-controlling interest   9,389  10,837  Total Liabilities & Shareholders Equity  76,304  71,915    1